Media headlines about Pacira Pharmaceuticals (NASDAQ:PCRX) have trended somewhat positive recently, according to Alpha One Sentiment. The research firm, a service of Accern, identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.06 on Alpha One’s scale. Alpha One also gave headlines about the company an impact score of 57 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected AlphaOne Sentiment’s scoring:
- Pacira Pharmaceuticals, Inc. (PCRX) Expected to Post Quarterly Sales of $74.57 Million (americanbankingnews.com)
- Pacira Pharma (PCRX) Appoints Mark Froimson to Board of Directors – StreetInsider.com (streetinsider.com)
- Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors (finance.yahoo.com)
- Suntrust Banks Inc. Buys 2385 Shares of Pacira Pharmaceuticals, Inc. (PCRX) (cote-ivoire.com)
- Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference (finance.yahoo.com)
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) traded up 1.57% during trading on Tuesday, hitting $45.35. The stock had a trading volume of 236,363 shares. Pacira Pharmaceuticals has a 52-week low of $29.95 and a 52-week high of $58.95. The firm’s market cap is $1.82 billion. The firm’s 50-day moving average is $46.37 and its 200 day moving average is $42.77.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, May 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Pacira Pharmaceuticals had a negative return on equity of 32.55% and a negative net margin of 28.67%. The firm had revenue of $69.30 million for the quarter, compared to analyst estimates of $70.30 million. During the same quarter in the prior year, the company earned $0.15 EPS. Pacira Pharmaceuticals’s revenue was up 5.8% on a year-over-year basis.
Several brokerages have issued reports on PCRX. HC Wainwright set a $59.00 target price on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, May 6th. Royal Bank Of Canada started coverage on Pacira Pharmaceuticals in a research note on Thursday, April 13th. They issued an “outperform” rating and a $58.00 price objective on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pacira Pharmaceuticals in a research note on Friday, May 5th. Mizuho decreased their target price on Pacira Pharmaceuticals from $57.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, May 5th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $60.00 target price on shares of Pacira Pharmaceuticals in a research note on Tuesday, March 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $55.25.
TRADEMARK VIOLATION WARNING: “Pacira Pharmaceuticals (PCRX) Earns Daily Coverage Optimism Score of 0.06” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.thestockobserver.com/2017/06/20/pacira-pharmaceuticals-pcrx-receives-news-sentiment-rating-of-0-06-updated-updated.html.
In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 1,877 shares of the business’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $81,311.64. Following the completion of the transaction, the chief accounting officer now directly owns 13,773 shares in the company, valued at approximately $596,646.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Scott Braunstein sold 768 shares of the business’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $33,269.76. Following the completion of the transaction, the senior vice president now owns 9,982 shares of the company’s stock, valued at $432,420.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,564 shares of company stock worth $2,506,682. 6.60% of the stock is owned by corporate insiders.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.